News

Basle, Switzerland, June 11, 2018. Memo Therapeutics AG announces that Dr. Karsten Fischer was appointed as Chief Executive Officer of …

Basel, Switzerland, May 9th 2018 – MEMO Therapeutics AG (“MEMO”), an innovator in the field of
antibody discovery and human …

Memo Therapeutics made it to the top 100 of Swiss startups for the third time in a row and is …

Memo Therapeutics AG was awarded a new CTI grant
MEMO has secured a third CTI …

Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform
 
Basel/Zurich, Switzerland, May 23, …

MEMO at conferences
MEMO presented in the investment stream at SNB 2017 in Zurich this year. Link to the conference …

Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.
Basel/Zurich, …

MEMO’s poster introducing the MemoMAB™ technology platform for the banking and screening of human immunoreceptor libraries was selected for the …

MEMO’s abstract has been accepted for Poster Discussion presentation during the ESMO Symposium on Immuno-Oncology – Advances in cancer immunotherapy; …

Memo Therapeutics made it to the top 100 of Swiss startups for the second time in a row and is …